動物胃食道逆流症市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、動物種類、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

全球動物胃食道逆流症市場預計將從 2025 年的 35.6 億美元成長到 2031 年的 59.2 億美元，複合年成長率達到 8.85%。

此細分市場包括專門用於緩解伴侶動物胃酸倒流的專用診斷工具和藥物治療，例如質子幫浦阻斷劑和H2受體拮抗劑。推動這一成長的主要動力是寵物人性化的趨勢。這導致飼主更願意投資先進的獸醫保健，同時也導致老年寵物胃腸道疾病的盛行率上升。正如美國寵物產品協會在2024年指出的那樣，美國寵物行業的總支出達到1520億美元，其中398億美元用於獸醫保健和產品，這表明飼主願意為寵物的健康承擔相當大的經濟負擔。

然而，長期獸醫護理和特殊診斷程序的高昂費用對市場發展構成重大障礙。這些巨額費用令注重預算的寵物飼主望而卻步，可能限制綜合治療方案的廣泛實施，並減緩整個產業的成長速度。因此，價格敏感性仍然是一個重大挑戰，阻礙了動物胃食道逆流症綜合管理方案的推廣，並減緩了市場擴張。

市場促進因素

全球寵物飼養量的激增和寵物人性化的趨勢正在從根本上改變人們對專業獸醫護理的需求，尤其是對胃食道逆流（GERD）等慢性疾病的需求。隨著飼主越來越將寵物視為家庭成員，他們更傾向於關注反流和吞嚥困難等令人痛苦的症狀，並及時尋求獸醫治療。這種情感紐帶推動了診斷和藥物治療方案使用量的增加，從而擴大了抑酸劑的市場。根據英國寵物食品協會發布的《2024年寵物數量》報告，英國約有1,720萬戶家庭飼養寵物，佔總人口的60%。這導致需要治療慢性消化系統疾病的患者群體龐大且持續成長。

此外，由於體重過重導致胃腸功能顯著受損，飲食誘發和肥胖相關的逆流性疾病日益增多，這成為推動市場成長的關鍵臨床催化劑。肥胖會增加腹內壓，導致括約肌功能障礙和慢性胃酸逆流，需要長期服藥。然而，由於飼主缺乏相關意識，早期治療往往受阻。根據寵物肥胖預防協會於2024年5月發布的《2023年全國寵物體重和營養調查》，只有17%的狗飼主意識到他們的寵物超重，這與臨床盛行率有顯著差異。這種認知差距表明，隨著診斷意識的提高，以及該行業強勁的經濟基礎，市場潛力巨大。例如，碩騰公司在2024年公佈的2023年全年銷售額為85億美元。

市場挑戰

長期獸醫護理和特殊診斷程序的高昂費用是全球動物胃食道逆流（GERD）市場成長的主要障礙。準確診斷通常需要內視鏡檢查和特殊pH值監測等昂貴的檢查，而有效治療則需要長期服用質子幫浦阻斷劑等藥物。這些經濟負擔對價格敏感的寵物飼主來說是一大障礙，常常導致必要的診斷測試延誤和維持治療中斷。因此，部分寵物得不到治療，從而降低了潛在的市場收入。

這種經濟負擔也體現在近期的行業指標中，這些指標顯示價格上漲正在影響消費者的行為。據美國獸醫協會（AVMA）稱，2024年對數千家診所的數據分析顯示，與前一年相比，寵物就診量下降了2.3%，這一趨勢主要歸因於飼主因服務成本上漲而減少就診次數。就診量的下降直接阻礙了市場發展，減少了獸醫診斷和治療複雜胃腸道疾病的機會，從而抑制了反流性疾病藥物的使用。

市場趨勢

針對短頭犬種量身定做的治療通訊協定的採用，正在迅速改變全球動物胃食道逆流症市場的臨床標準。獸醫們日益認知到短頭犬阻塞性氣道症候群（BOAS）、食道裂孔疝氣和慢性胃酸倒流之間的聯繫，因此引入了將外科氣道矯正與長期抑制胃酸分泌相結合的專門治療方法。這種針對特異性犬種的治療方法得益於扁臉犬種經久不衰的受歡迎程度，因為這些犬種在基因上比其他犬種需要更多的胃腸道護理。根據美國犬業俱樂部2024年3月報告，法國鬥牛犬仍然是註冊數量最多的犬種，註冊數量高達98,500只，確保了需要這些針對性反流管理策略的患者數量穩定。

同時，治療性胃腸道飲食和營養管理的廣泛應用，正將治療策略從依賴藥物轉向更全面、保守的方法。業界領導企業正積極拓展其產品線，提供易於消化、低脂的處方糧和腸道菌叢增強補充劑，旨在緩解逆流症狀，改善食道動力，並避免長期用藥帶來的副作用。這一趨勢反映了功能性保健產品在消化系統治療中的輔助作用，這些產品可與標準質子幫浦阻斷劑相輔相成。根據《寵物食品產業雜誌》（2024年2月刊）報道，普瑞納Pro Plan獸用營養補充劑的銷售額在2023年成長了22.6%，顯示用於改善消化健康的營養干預措施正在迅速商業性。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：動物胃食道逆流症全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 產品類別（診斷、治療、其他）
  • 動物種類（伴侶動物、家畜）
  • 給藥途徑（口服、注射）
  • 分銷通路（獸醫院/診所、零售藥局、電子商務）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美動物胃食道逆流症市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲動物胃食道逆流症市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區動物胃食道逆流症市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲動物胃食道逆流症市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲動物胃食道逆流症市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球動物胃食道逆流症市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Zoetis Inc.
• Merck & Co., Inc.
• Elanco Animal Health Inc.
• Ceva Sante Animale SA
• Boehringer Ingelheim International GmbH
• McNeil Consumer Pharmaceuticals Co.
• BioZyme, Inc.
• Annamaet Petfoods Inc.
• Hill's Pet Nutrition, Inc.
• Blue Buffalo Co., Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Animal Gastroesophageal Reflux Disease Market is projected to expand from USD 3.56 Billion in 2025 to USD 5.92 Billion by 2031, achieving a CAGR of 8.85%. This market sector encompasses specialized diagnostic tools and pharmaceutical treatments, such as proton pump inhibitors and H2 receptor antagonists, specifically formulated to alleviate acid reflux in companion animals. Growth is primarily propelled by the pet humanization trend, which has fostered a greater willingness among owners to fund advanced veterinary healthcare, alongside an increasing prevalence of gastrointestinal ailments in aging pet populations. As highlighted by the American Pet Products Association in 2024, total U.S. pet industry spending hit $152 billion, with $39.8 billion directed toward veterinary care and products, demonstrating the substantial financial dedication owners have toward animal well-being.

However, the high expenses linked to long-term veterinary care and specialized diagnostic procedures pose a significant obstacle to market progression. These substantial costs can establish a barrier for budget-conscious pet owners, potentially restricting the broad implementation of thorough treatment regimens and decelerating the sector's overall growth rate. Consequently, price sensitivity remains a critical challenge that could impede the widespread adoption of comprehensive management plans for animal gastroesophageal reflux disease, thereby slowing the expansion of the market.

Market Driver

The surge in global pet ownership and the trend of humanization are fundamentally transforming the demand for specialized veterinary therapeutics, especially for chronic ailments like gastroesophageal reflux disease. As owners increasingly regard companion animals as family members, they are more likely to seek immediate veterinary care for symptoms of distress, such as regurgitation or dysphagia, rather than ignoring them. This emotional connection drives higher utilization of diagnostic and pharmaceutical solutions, broadening the market for acid suppressants. Data from UK Pet Food's 'Pet Population 2024' report indicates that roughly 17.2 million households in the United Kingdom own a pet, accounting for 60 percent of the population, providing a vast and growing patient base for managing chronic digestive health conditions.

Additionally, the increasing prevalence of diet-induced and obesity-related reflux acts as a pivotal clinical catalyst for market growth, given that excess weight severely impairs gastrointestinal function. Obesity elevates intra-abdominal pressure, resulting in sphincter dysfunction and chronic acid reflux that requires ongoing pharmacological treatment. Despite this, early treatment is often hindered by a lack of owner awareness; the Association for Pet Obesity Prevention's '2023 National Pet Weight and Nutrition Survey' from May 2024 noted that only 17 percent of dog owners identified their pets as overweight, contrasting sharply with clinical prevalence. This gap highlights significant latent market potential as diagnostic awareness rises, further supported by the sector's strong economic foundation, evidenced by Zoetis reporting full-year 2023 revenue of $8.5 billion in 2024.

Market Challenge

The substantial expenses required for long-term veterinary management and specialized diagnostic procedures represent a major hurdle to the expansion of the Global Animal Gastroesophageal Reflux Disease Market. Accurate diagnosis often demands costly interventions like endoscopy or specialized pH monitoring, while effective treatment relies on the chronic administration of medications such as proton pump inhibitors. These financial requirements form a formidable barrier for price-sensitive pet owners, frequently resulting in the postponement of essential diagnostic screenings or the cessation of maintenance therapies, which ultimately reduces potential market revenue as segments of the pet population remain untreated.

This financial strain is reflected in recent industry metrics showing that escalating prices are influencing client behavior. According to the American Veterinary Medical Association, data analyzed in 2024 from thousands of practices indicated a 2.3% decline in patient visits compared to the previous year, a trend largely driven by rising service costs compelling budget-conscious owners to restrict veterinary visits. This decrease in clinical traffic directly impedes the market by reducing opportunities for veterinarians to diagnose and treat complex gastrointestinal disorders, thereby stalling the wider uptake of reflux disease therapeutics.

Market Trends

The adoption of Brachycephalic-Focused Treatment Protocols is swiftly altering clinical standards within the Global Animal Gastroesophageal Reflux Disease Market. Veterinarians are increasingly associating Brachycephalic Obstructive Airway Syndrome (BOAS) with hiatal hernias and chronic acid reflux, leading to specialized therapeutic regimens that integrate surgical airway correction with long-term acid suppression. This breed-specific approach is fueled by the enduring popularity of flat-faced dogs, which genetically demand significantly more gastrointestinal care than other breeds. As reported by the American Kennel Club in March 2024, French Bulldogs remained the most registered breed with 98,500 registrations, guaranteeing a steady stream of patients needing these targeted reflux management strategies.

Concurrently, the proliferation of Therapeutic Gastrointestinal Diets and Nutrition is transforming management strategies by emphasizing multimodal conservative therapy over sole reliance on pharmaceuticals. Industry leaders are vigorously expanding their offerings of highly digestible, low-fat prescription diets and microbiome-enhancing supplements aimed at alleviating reflux symptoms and boosting esophageal motility without the side effects associated with chronic medication. This movement mirrors a wider consumer shift toward functional wellness products serving as complementary treatments to standard proton pump inhibitors. According to Petfood Industry in February 2024, Purina Pro Plan Veterinary Supplement sales surged by 22.6% in 2023, highlighting the swift commercial adoption of nutritional interventions for digestive health.

Key Market Players

• Zoetis Inc.
• Merck & Co., Inc.
• Elanco Animal Health Inc.
• Ceva Sante Animale S.A.
• Boehringer Ingelheim International GmbH
• McNeil Consumer Pharmaceuticals Co.
• BioZyme, Inc.
• Annamaet Petfoods Inc.
• Hill's Pet Nutrition, Inc.
• Blue Buffalo Co., Ltd.

Report Scope

In this report, the Global Animal Gastroesophageal Reflux Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Animal Gastroesophageal Reflux Disease Market, By Product

• Diagnostics
• Treatment
• Others

Animal Gastroesophageal Reflux Disease Market, By Animal Type

• Companion Animals
• Livestock Animals

Animal Gastroesophageal Reflux Disease Market, By Route of Administration

• Oral
• Injectable

Animal Gastroesophageal Reflux Disease Market, By Distribution Channel

• Veterinary hospitals & clinics
• Retail Pharmacies
• E-commerce

Animal Gastroesophageal Reflux Disease Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Animal Gastroesophageal Reflux Disease Market.

Available Customizations:

Global Animal Gastroesophageal Reflux Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Animal Gastroesophageal Reflux Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Diagnostics, Treatment, Others)
  • 5.2.2. By Animal Type (Companion Animals, Livestock Animals)
  • 5.2.3. By Route of Administration (Oral, Injectable)
  • 5.2.4. By Distribution Channel (Veterinary hospitals & clinics, Retail Pharmacies, E-commerce)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Animal Gastroesophageal Reflux Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Animal Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Animal Gastroesophageal Reflux Disease Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Animal Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Animal Gastroesophageal Reflux Disease Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Animal Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Animal Gastroesophageal Reflux Disease Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Animal Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel

7. Europe Animal Gastroesophageal Reflux Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Animal Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Animal Gastroesophageal Reflux Disease Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Animal Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Animal Gastroesophageal Reflux Disease Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Animal Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Animal Gastroesophageal Reflux Disease Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Animal Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Animal Gastroesophageal Reflux Disease Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Animal Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Animal Gastroesophageal Reflux Disease Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Animal Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Animal Gastroesophageal Reflux Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Animal Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Animal Gastroesophageal Reflux Disease Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Animal Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Animal Gastroesophageal Reflux Disease Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Animal Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Animal Gastroesophageal Reflux Disease Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Animal Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Animal Gastroesophageal Reflux Disease Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Animal Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Animal Gastroesophageal Reflux Disease Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Animal Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Animal Gastroesophageal Reflux Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Animal Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Animal Gastroesophageal Reflux Disease Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Animal Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Animal Gastroesophageal Reflux Disease Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Animal Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Animal Gastroesophageal Reflux Disease Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Animal Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. South America Animal Gastroesophageal Reflux Disease Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Animal Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Animal Gastroesophageal Reflux Disease Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Animal Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Animal Gastroesophageal Reflux Disease Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Animal Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Animal Gastroesophageal Reflux Disease Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Animal Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Animal Gastroesophageal Reflux Disease Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zoetis Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck & Co., Inc.
• 15.3. Elanco Animal Health Inc.
• 15.4. Ceva Sante Animale S.A.
• 15.5. Boehringer Ingelheim International GmbH
• 15.6. McNeil Consumer Pharmaceuticals Co.
• 15.7. BioZyme, Inc.
• 15.8. Annamaet Petfoods Inc.
• 15.9. Hill's Pet Nutrition, Inc.
• 15.10. Blue Buffalo Co., Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer